

Supplemental Table 1: Baseline characteristics of study population included in the primary cardiovascular outcomes analysis (n=18,036).

| <b><u>Characteristic</u></b>               | <b><u>Resistant</u></b> | <b><u>Non-Resistant</u></b> | <b><u>p-value</u></b> |
|--|-------------------------|-----------------------------|-----------------------|
|  | <b><u>N=2,521</u></b>   | <b><u>N=15,515</u></b>      |                       |
| <b>Gender</b>                              |                         |                             | <0.01                 |
| Male                                       | 49.8%                   | 44.4%                       |                       |
| <b>Race</b>                                |                         |                             | <0.01                 |
| Black                                      | 8.1%                    | 8.7%                        |                       |
| Missing                                    | 14.2%                   | 13.8%                       |                       |
| Other                                      | 19.0%                   | 23.6%                       |                       |
| White                                      | 58.7%                   | 53.9%                       |                       |
| <b>Age*</b>                                | 57.8 (57.4-58.3)        | 56.6 (56.4-56.8)            | <0.01                 |
| <b>Baseline Systolic BP*</b>               | 153.8 (153.1-154.5)     | 145.1 (144.9-145.4)         | <0.01                 |
| <b>Baseline Diastolic BP*</b>              | 85.7 (85.2-86.2)        | 83.5 (83.3-83.7)            | <0.01                 |
| <b>Body Mass Index*</b>                    | 31.5 (31.2-31.9)        | 30.3 (30.0-30.6)            | <0.01                 |
| <b>Current smoker</b>                      |                         |                             |                       |
| Yes  | 10.9%                   | 10.1%                       | 0.21                  |
| <b>Site</b>                                |                         |                             | 0.04                  |
| Kaiser Northern California                 | 95.7%                   | 96.6%                       |                       |
| Kaiser Colorado                            | 4.3%                    | 3.4%                        |                       |
| <b>Year of hypertension registry entry</b> |                         |                             | <0.01                 |
| 2000                                       | 2.7%                    | 2.1%                        |                       |
| 2001                                       | 15.7%                   | 17.0%                       |                       |
| 2002                                       | 37.8%                   | 33.5%                       |                       |
| 2003                                       | 20.5%                   | 21.5%                       |                       |
| 2004                                       | 11.9%                   | 13.3%                       |                       |
| 2005                                       | 6.9%                    | 8.2%                        |                       |

|   |       |       |       |
|---|-------|-------|-------|
| 2006  | 4.5%  | 4.4%  |       |
| <b><u>Baseline co-morbidities</u></b>           |       |       |       |
| Albuminuria                                     | 0.3%  | 0.2%  | 0.27  |
| Alcohol abuse                                   | 4.0%  | 3.4%  | 0.13  |
| Angina  | 0.5%  | 0.6%  | 0.69  |
| Asthma  | 9.2%  | 12.5% | <0.01 |
| Atrial fibrillation                             | 1.9%  | 1.1%  | <0.01 |
| Bipolar   | 0.8%  | 0.8%  | 0.86  |
| Diabetes  | 16.4% | 8.2%  | <0.01 |
| Depression                                      | 9.8%  | 14.0% | <0.01 |
| Drug abuse                                      | 9.8%  | 14.0% | <0.01 |
| Peripheral Vascular Disease                     | 0.8%  | 0.8%  | 0.81  |
| Sleep apnea                                     | 2.2%  | 2.2%  | 0.85  |
| <b><u>Baseline Hypertension Medications</u></b> |       |       |       |
| Beta Blockers                                   | 77.7% | 65.4% | <0.01 |
| ACE/ARB   | 67.9% | 68.6% | 0.43  |
| All Diuretics                                   | 93.1% | 93.3% | 0.66  |
| K-sparing Diuretics                             | 36.7% | 38.2% | 0.16  |
| Calcium Channel Blocker                         | 28.0% | 22.6% | <0.01 |
| Alpha Adrenergic Blocker                        | 8.2%  | 6.7%  | <0.01 |
| Peripheral Vasodilators                         | 0.6%  | 0.3%  | 0.05  |

---

\*Continuous variables are presented as mean and 95% confidence interval.